PSEN1 and Cognitive impairment: Significant improvements were found in 100 mg/kg SCM-198- and DON-treated groups (F (4, 47) = 6.333, p = 0.0004, Figure 1C), indicating the neuroprotective effects of SCM-198 in ameliorating cognitive impairment of AβPP/PS1 mice.